Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MITRAL VALVE STENOSIS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29Linked to original sources
PubMed1997

Echocardiographic assessment of commissural calcium: a simple predictor of outcome after percutaneous mitral balloon valvotomy.

OBJECTIVES: This study was undertaken to determine whether the presence of calcium in the mitral valve commissures, as demonstrated echocardiographically, could predict outcome and to compare this with an established echocardiographic scoring system. BACKGROUND: Percutaneous mitral balloon valvotomy is an effective form of treatment for mitral valve stenosis. It is important to identify patients who would benefit from this procedure. Commissural splitting is the dominant mechanism by which mitral valve stenosis is relieved by this technique, and thus commissural morphology may predict outcome. METHODS: One hundred forty-nine consecutive patients who underwent percutaneous mitral balloon valvotomy at the Mayo Clinic were evaluated retrospectively. The morphology of the mitral valve apparatus on the baseline echocardiograms was scored in blinded manner using a semiquantitative grading system of leaflet thickening, mobility, calcification and subvalvular thickening (Abascal score). Additionally, each of the medial and lateral commissures was graded for the presence or absence of calcification. End points were death, New York Heart Association functional class, repeat percutaneous mitral balloon valvotomy and mitral valve replacement at follow-up. RESULTS: The mean follow-up period was 1.8 years (maximum 7.9 years). Univariate predictors of death and all events combined included age, the use of a double-balloon technique, the presence of calcium in a commissure and the Abascal score, as continuous variables. Patients with an Abascal score < or = 8 showed a trend toward improved survival at 36 months free of death, repeat percutaneous mitral balloon valvotomy or mitral valve replacement (78 +/- 6% vs. 67 +/- 8%, p = 0.07) and free of all events combined (75 +/- 6% vs. 64 +/- 8%, p = 0.07) versus those patients with a score > 8. However, survival at 36 months free of death, repeat percutaneous mitral balloon valvotomy or mitral valve replacement (86 +/- 4% vs. 40 +/- 4%) and free of all events combined (82 +/- 5% vs. 38 +/- 10%) at follow-up was significantly different between patients without commissural calcium and those with commissural calcium (p < 0.001). In a Cox regression model with Abascal score and commissural calcium and their interaction, calcification emerged as the only significant variable (p < 0.01). CONCLUSIONS: The presence of commissural calcium is a strong predictor of outcome after percutaneous mitral balloon valvotomy. Patients with evidence of calcium in a commissure have a lower survival rate and a higher incidence of mitral valve replacement and all end points combined. Thus, the simple presence or absence of commissural calcification assessed by two-dimensional echocardiography can be used to predict outcome.

Calcinosis↗
PubMed1995

Papillary fibroelastoma of the mitral valve associated with rheumatic mitral stenosis.

Papillary fibroelastoma of the mitral valve diagnosed and treated in life is extremely rare. There have been eight cases documented so far. We report the first case of a mitral valve papillary fibroelastoma associated with severe rheumatic mitral stenosis and tricuspid regurgitation with stenosis. The tumor arose from the posteromedial papillary muscle of the mitral valve. The mitral valve was replaced after excising the valve with the tumor and the tricuspid valve was repaired. The patient did well and remains asymptomatic.

Echocardiography, Transesophageal↗
PubMed2004

Treatment with epoprostenol of pulmonary arterial hypertension following mitral valve replacement for mitral stenosis.

Pulmonary hypertension frequently complicates mitral stenosis. Increased pulmonary artery pressure results from raised left atrial pressure, pulmonary arteriolar constriction, and obliterative changes in the pulmonary vascular bed, and usually responds to surgical relief of mitral stenosis. However, severe pulmonary hypertension may persist after surgical treatment of mitral stenosis. We describe a patient whose severe pulmonary hypertension following mitral valve replacement was treated successfully with continuous intravenous epoprostenol.

Antihypertensive Agents↗
PubMed1993

Heart valve surgery.

Progress in valve repair and replacement continued over the past year. Aortic valve repair for aortic insufficiency appears promising, and aortic decalcification may still be a useful alternative in certain cases of aortic stenosis. Mitral valve repair, well accepted for myxomatous valves, presents a challenge in ischemic disease. Balloon mitral valvotomy offers significant short-term hemodynamic improvement, but needs to be properly compared with surgical treatment of mitral stenosis. Although aortic valve replacement with homografts and pulmonary autografts yields excellent results, enthusiasm for the stentless porcine xenograft is increasing. Clinical results reported for the Carpentier-Edwards pericardial valve (Baxter Healthcare Corp., Edwards Div., Santa Ana, CA) and the Bjork-Shiley monostrut valve (Shiley Inc., Irvine, CA) are excellent. Acute endocarditis continues to be a challenging problem but early aggressive debridement appears to offer patients the best chance of cure, regardless of what valve replacement is used.

Aortic Valve↗
PubMed1990

[Percutaneous mitral valvuloplasty].

Since its introduction as an alternative to surgical commissurotomy, percutaneous mitral valvuloplasty (PMV) has been performed in a large number of patients with mitral valve stenosis. PMV significantly improves valvular function, the final increase in mitral valve area being about 2 sq cm. The quality of the results obtained is principally related to the anatomy of the valve. The overall incidence of complications is low. The mortality rate ranges from 0.5 to 4 p. 100 in severe mitral stenosis. Left-to-right atrial shunting is detected by oximetry in 20 p. 100 of the cases, but it subsequently disappears in two thirds of the patients; late results are only known at medium term. When the initial result is satisfactory functional improvement is the rule and the incidence of restenosis is low. When the initial result is insufficient, or when mitral stenosis develops open heart surgery is usually necessary. The decision to perform PMV should only be made after exclusion of its contraindications: left atrial thrombosis, moderate to severe mitral stenosis. Because of the encouraging results obtained, PMV can be envisaged as first choice treatment of mitral stenosis with flexible cusps. In calcified mitral stenosis the standard treatment is mitral valve replacement, PMV being reserved to some particular cases.

Adolescent↗
PubMed1998

Inhaled corticosteroid improves bronchial reactivity and decreases symptoms in patients with mitral stenosis.

STUDY OBJECTIVE: To determine if treatment with inhaled budesonide forte can diminish increased bronchial hyperreactivity and improve symptoms in patients with mitral valve stenosis. DESIGN: The study was randomized, double blind, and placebo controlled. SETTING: Outpatient/university hospital. PATIENTS: Twelve subjects, 8 female and 4 male, who qualified for mitral valve replacement. All subjects presented with increased bronchial reactivity to histamine at the time of the study. INTERVENTIONS: Patients received placebo or budesonide forte twice a day (1,200 mg/d) for 6 weeks. During the study, patients were treated with the same doses of diuretics and other medications that could affect bronchial reactivity. MEASUREMENTS: Spirometry, provocative concentration of histamine causing a 20% fall in the FEV1 (PC20H), symptom scores. RESULTS: In the treated group, the initial PC20H was 0.82+/-0.72 mg/mL; in the placebo group 1.39+/-1.3 mg/mL. After 6 weeks of treatment, PC20H was significantly higher (3.07+/-2.28 mg/mL; p > 0.01) in the budesonide-treated group and remained unchanged in the placebo group (1.49+/-0.91). Symptom scores were significantly lower after administration of budesonide forte (mean change, 4.0+/-2.6). CONCLUSIONS: Six weeks of treatment with budesonide forte significantly decreased bronchial reactivity to histamine and improved symptoms in patients with mitral valve stenosis.

Administration, Inhalation↗
PubMed1993

Replacement of chordae tendineae using expanded polytetrafluoroethylene (ePTFE) sutures during mitral valve replacement in patients with severe mitral stenosis.

Since September 1991, 20 patients with mitral stenosis underwent mitral valve replacement and chordal replacement with expanded polytetrafluoroethylene (ePTFE) sutures. The continuity between the papillary muscles and the mitral annulus was maintained by four mattress sutures of ePTFE, which connected the stumps of the papillary muscle heads to the mitral annulus at the 2, 4, 8, and 10 o'clock positions. Low profile bileaflet prosthetic valves were inserted. There was no mortality either in-hospital or during follow-up. There was no valve related morbidity, such as valve structural failure, thromboembolism, anticoagulant related hemorrhage, prosthetic valve endocarditis, or posterior left ventricular rupture. The technique of replacing chordae tendineae is described in detail.

Chordae Tendineae↗
PubMed1999

[Anesthetic management for mitral valve replacement in a patient with mitral stenosis and dilated cardiomyopathy].

A 42-year-old man with dilated cardiomyopathy and rheumatic mitral stenosis underwent mitral valve replacement. Prior intravascular fluid administration and infusion of dopamine and dobutamine stabilized hemodynamics during the induction of anesthesia. High-dose fentanyl at pre-cardiopulmonary bypass period and circulatory assist with milrinone and intraaortic balloon pumping after the bypass enabled us to obtain stable hemodynamics. Preoperative dobutamine stress test provided us the effective information for circulatory management in this patient.

Adult↗
PubMed1988

Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk.

The incidence of left atrial spontaneous echo contrast was evaluated in 52 patients with isolated or predominant mitral valve stenosis (Group 1) and 70 other patients who had undergone mitral valve replacement (Group 2). All patients were studied by conventional transthoracic and transesophageal two-dimensional echocardiography. Spontaneous echo contrast could be visualized within the left atrium in 35 Group 1 patients (67.3%) (including 7 patients with sinus rhythm) and 26 Group 2 patients (37.1%) (all with atrial fibrillation). Patients with spontaneous echo contrast had a significantly larger left atrial diameter and a greater incidence of both left atrial thrombi and a history of arterial embolic episodes than did patients without spontaneous echo contrast. Association between spontaneous echo contrast and left atrial thrombi and a history of arterial embolization (considered individually or in combination) showed a high sensitivity and negative predictive value. It is concluded that spontaneous echo contrast is a helpful finding for identification of an increased thromboembolic risk in patients with mitral stenosis and after mitral valve replacement.

Adult↗
PubMed1986

Detection of spontaneous echocardiographic contrast within the left atrium by transesophageal echocardiography: spontaneous echocardiographic contrast.

Transesophageal echocardiography was performed in 314 patients over a period of 24 months using a 3.5 MHz phased-array system fitted to the distal end of a conventional 12 mm endoscope. In 12 patients (2.6%) transesophageal echocardiography could not be performed because of adverse reaction to the gastroscopic procedure. Side effects were a transient A-V block in one patient and asthmatic attack in another. Mitral valve lesions were found in 99 of 314 patients. In 9 of these 99 patients (11%), including 1 patient with mitral valve stenosis and sinus rhythm, 2 with atrial fibrillation, 3 with disc, and 3 with porcine mitral prosthesis, spontaneous echocardiographic contrast was found within the left atrium, described as faint echoes in 2 patients and dense echoes filling the whole left atrium and following turbulent flow in the other 7 patients. Only in 2 patients was left atrium shown to have additional echoes within its cavity in the four-chamber view by transthoracic echocardiography. Signs of cerebral emboli were found in 5 of 9 patients and of peripheral embolism in 3 of 9 patients. Their mechanism seems to involve red cell aggregation, which is greatest at low flow velocity such as in dilated left atria in the case of mitral valve stenosis or prosthesis. The additional effect of platelet aggregation must be discussed because increased platelet aggregation was detected in all patients with spontaneous echocardiographic contrast. Transesophageal echocardiography seems to be of great diagnostic value in patients with mitral valve lesions and cerebral and peripheral embolism, giving new insight into the pathophysiologic mechanism and possibly improving the therapeutic approach in the near future.

Adult↗
PubMed1990

[Echocardiography quantification of mitral valve defects].

Echocardiography led during the last 10 years to a definite improvement of quality of cardiological diagnostics. In addition to an excellent recording of morphological and functional changes of the heart by 1- and two-dimensional images Doppler-echocardiography allows the semiquantitative judgement of the hemodynamic effect. Echocardiographic techniques try to measure the mitral valve area in cases of mitral stenosis resp. the leak area in cases of mitral insufficiency to assess the importance of valve disorder. These parameters are constant values, whereas the transmitral diastolic pressure gradient and the regurgitant volume are variable. The assessment of the mitral valve area and the graduation of the mitral valve stenosis is possible with a high diagnostic relevance using planimetrical and/or pressure-half-time methods. The applicability of the pressure-half-time method depends on the nature of the pressure decrease and an individual review is necessary. The measurement of the leak area is much more problematical. The assessment of the functional regurgitation area by colour coded Doppler-echocardiography seems to be favourite, but not validated up to now. A semiquantitative judgement of a mitral valve insufficiency is successful in evaluating of intensity, width and area of the regurgitant cloud. The evaluation of raw data of flow patterns will provide further information in future.

Echocardiography↗
PubMed2004

Antithrombotic therapy in native heart valve disease.

In establishing the indication for anticoagulation of patients with native heart valve disease, those with thromboembolic events and/or atrial fibrillation (AF) must be distinguished from patients with sinus rhythm. Anticoagulation should be started as a matter of principle in patients with thromboembolic events and/or AF who do not undergo valve replacement. However, a more differentiated procedure is mandatory for patients with sinus rhythm. If the left atrium is enlarged, spontaneous echo contrast is detected, and/or there is no atrial contraction and/or reduced left ventricular pump function (e.g., in patients with mitral valve stenosis), then anticoagulation with a target INR of 2.5 is indicated, even in those with sinus rhythm. Whereas rheumatic mitral valve stenosis predominates in developing countries, aortic stenosis (AS) predominates in developing countries. These AS patients mainly suffer microemboli that often determine the prognosis in patients with calcification of the mitral annulus. Anticoagulation is not recommended in calcific microemboli. If there are simultaneous atherothrombotic plaques of the aortic arch > 5 mm in size owing to an often more complex cardiovascular risk profile, then warfarin treatment is indicated. Mitral valve prolapse (MVP), patient foramen ovale and atrial septal aneurysm are potential sources of embolism that may cause stroke. On their own, these congenital lesions do not entail an indication for anticoagulation. This applies in particular to patients with MVP in whom secondary prevention of stroke can be attained with 100 mg aspirin.

Anticoagulants↗
PubMed1997

Calculation of mitral valve area in mitral stenosis using the proximal isovelocity surface area method. Comparison with two-dimensional planimetry and Doppler pressure half time method.

Two-dimensional echocardiographic (2-D) planimetry and the Doppler pressure half-time (PHT) method have been used to estimate mitral valve area (MVA) in patients with mitral stenosis (MS). Recently, the proximal isovelocity surface area (PISA) method has been shown to be accurate for calculating MVA. The purpose of this study was to compare the PISA method with previous methods. Thirty patients with MS were studied; 17 had pure MS, 4 combined mild MR, 6 combined mild AR, and 3 combined MR and AR. Color Doppler flow mapping was performed at an aliasing (blue-red interface) velocity of 14 cm/sec using the zero-baseline shift. MVA was calculated as 2 x 3.14 x R2 x 14 x (theta/180) / PFV, where R is the distance from aliasing to orifice, 14 is the aliasing velocity, theta is the internal angle of the mitral valve, and PFV is the peak flow velocity at the mitral orifice. MVA was also calculated using the 2-D and PHT methods, and compared with the PISA method. MVA calculated using the PISA method correlated well with the 2-D (r=0.90, p < 0.01, SEE = 0.18 cm2) and PHT methods (r=0.82, p < 0.01, SEE = 0.24 cm2). Compared with the 2-D method, the standard error of the estimate of the PISA method was - 0.14+/-0.18 cm2 and the percent error was -10.4+/-18.9%. Compared with the PHT method, the standard error of the estimate of the PISA method was + 0.01+/-0.24 cm2 and the percent error was +3.4+/-34.6%. MVA calculated using the PISA method correlated well with the 2-D and PHT methods in patients with pure MS or with MS combined mild regurgitation. The PISA method may be useful for calculating MVA as an alternative method.

Adult↗
PubMed1998

[Current perspectives in screening for cardiac diseases which most frequently cause sudden death during the practice of a sports activity].

Sudden death during sports activities is extremely rare in athletes and sportsmen. Its occurrence was calculated at 0.77 to 13 deaths per 100,000 sportsmen/year. The most frequent causes were coronary heart disease, coronary muscular bridges, congenital coronary artery anomalies, subarachnoid hemorrhage, hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, Marfan syndrome, aortic coarctation, myocarditis, pulmonary embolism, aortic stenosis, mitral valve prolapse and WPW syndrome. Clinical examination nearly identifies all cases of aortic stenosis, mitral valve prolapse with regurgitation, and aortic coarctation but misses the majority of cases of hypertrophic cardiomyopathy and coronary artery diseases. The use of Chest x-rays, ECG, Stress Test and Echocardiogram will provide the identification of most cases with increased risk of death. Although costs are not limited for professional athletes, this strategy does not totally overcome the problem because diagnostic errors are frequent (false positives and false negatives). Therefore it is important to admit the failure of these screening procedures and the necessity to adapt the strategy to cost-efficiency and time-efficiency in this population.

Aortic Diseases↗
PubMed2006

Effects of annular size, transmitral pressure, and mitral flow rate on the edge-to-edge repair: an in vitro study.

BACKGROUND: Although edge-to-edge repair is an established adjunctive procedure, there is still debate on its long-term durability and efficacy. METHODS: Fifteen porcine mitral valves were studied in a physiologic left heart simulator with a variable size annulus (dilated = 8.22 cm2, normal = 6.86 cm2, contracted = 5.5 cm2). Mitral valves were tested under steady and physiologic pulsatile flow conditions (cardiac outputs: 4 to 6 L/min), at peak transmitral pressures between 100 mm Hg and 140 mm Hg. A miniature force transducer was used to measure the Alfieri stitch force (F(A)). Mitral flow rate (MFR), transmitral pressure, effective orifice area, mitral regurgitation, and F(A) were monitored. RESULTS: The edge-to-edge repair led to a decrease in effective orifice area of 16.55% +/- 8.22%; further reduction in effective orifice area was attained with annular contraction. Mitral regurgitation after the edge-to-edge repair was significantly higher (p <0.05) with annular dilation. In the pulsatile experiments, two peaks in F(A) were observed: one during systole (F(A) = 0.059 +/- 0.024 N) and a second during diastole (F(A) = 0.072 +/- 0.021 N). Multivariate analysis of variance analysis showed that during systole, transmitral pressure and mitral annular area (MAA) had significant effects on F(A) [F(A) = (4.40 x 10(-4)) transmitral pressure (mm Hg) + (5.0 x 10(-3)) MAA (cm2) - 0.05 (R2 = 0.80)], whereas during diastole MFR and MAA had significant effects on F(A) [F(A) = (1.03 x 10(-4)) MFR2 (L/min) - (1.60 x 10(-3)) MAA (cm2) + 0.02 (R2 = 0.90)]. CONCLUSIONS: With annular dilation, mitral regurgitation persisted even after the edge-to-edge repair. The edge-to-edge repair does not cause clinically relevant mitral valve stenosis in a normal size mitral valve. Mitral flow rate and transmitral pressure are the main determinants of F(A) during the cardiac cycle. Increasing annular area increases F(A) during systole but decreases F(A) during diastole. Systolic F(A) may become dominant with increases in MAA or peak transmitral pressure, or both.

Animals↗